Valuation: Biolidics Limited

Market Cap 60.67M 47.36M 41.02M 38.24M 35.17M 66.39M 4.5B 67.13M 449M 176M 2.25B 178M 174M 7.46B P/E 2024
-8.18x
P/E 2025 -22.5x
Enterprise Value 62.53M 48.81M 42.27M 39.41M 36.24M 68.42M 4.64B 69.18M 463M 182M 2.32B 183M 179M 7.69B EV / Sales 2024
58.8x
EV / Sales 2025 17.5x
Free-Float
44.94%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 46 30/04/2024
Comptroller/Controller/Auditor 44 01/07/2024
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 64 14/06/2021
Director/Board Member 55 31/03/2023
Director/Board Member 70 27/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 47.36M
+2.32%+0.24%+23.89%+5.32% 214B
+2.51%+1.61%+0.31%-21.63% 140B
+1.88%+6.26%-21.34%+21.30% 133B
-2.75%+3.69%-54.46%-5.88% 69.19B
-0.70%+3.74%+12.28%+11.84% 51.28B
+0.18%+5.51%-13.94%-19.55% 50.43B
+1.37%+0.58%+22.82%+11.73% 39.85B
+0.99%+5.41%+42.25%+37.98% 39.27B
+0.40%+4.55%-21.39%+24.98% 32.32B
Average +1.13%+3.77%-1.07%+7.34% 85.43B
Weighted average by Cap. +1.66%+3.04%+0.46%+3.78%

Financials

2024 2025
Net sales 858K 670K 580K 541K 497K 939K 63.68M 949K 6.35M 2.49M 31.86M 2.52M 2.46M 106M 5.26M 4.11M 3.56M 3.32M 3.05M 5.76M 390M 5.82M 38.96M 15.29M 195M 15.42M 15.08M 647M
Net income -3.43M -2.68M -2.32M -2.16M -1.99M -3.76M -255M -3.8M -25.43M -9.98M -128M -10.07M -9.85M -422M -3.96M -3.09M -2.68M -2.5M -2.3M -4.34M -294M -4.38M -29.34M -11.52M -147M -11.62M -11.36M -487M
Net Debt 1.46M 1.14M 984K 917K 843K 1.59M 108M 1.61M 10.78M 4.23M 54.04M 4.27M 4.17M 179M 1.86M 1.45M 1.25M 1.17M 1.08M 2.03M 138M 2.05M 13.75M 5.39M 68.93M 5.44M 5.32M 228M
Logo Biolidics Limited
Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services and investment holding. Its segments are Cancer, Infectious diseases, and Laboratory services, and Corporate segments. Its Cancer and infectious diseases segments involve the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship networks and direct customers in the cancer field, and the infectious diseases field. The Laboratory services segment involves the business, operation, and provision of laboratory services to customers. The laboratory has regulatory approval from Singapore’s Ministry of Health for testing for COVID-19 in Singapore.
Employees
-